Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. have announced that the FDA has approved Sucampo�s supplemental new drug application...
Sucampo and Takeda announced topline results from a pharmacodynamic, PK and tolerability Phase III study of a liquid formulation of...
Sucampo Pharmaceuticals,and Takeda Pharmaceutical Company Limited have announced that on October 17, 2014, they entered into a global license, development,...
Top line results are reported by Sucampo Pharma from an open-label 439 patient, 36 week, Phase III clinical trial designed...
A post-hoc analyses of two pivotal Phase III studies of Amitiza (lubiprostone), from Sucampo, for the treatment of Irritable Bowel...
The UK National Institute of Health and Care Excellence (NICE) has released a Final Appraisal Determination with guidance for the...
Mallinckrodt plc a leading global specialty pharmaceutical company, and Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, announced that they have...
Shionogi has announced pivotal phase III study (COMPOSE I) results showing that once-daily treatment with S 297995 (naldemedine) significantly improved...